Stay updated on Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page.

Latest updates to the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed descriptions of a clinical trial for metastatic castrate resistant prostate cancer and the addition of a new version revision. The name of the principal investigator and the collaborators have been retained, but the core content regarding the trial's objectives and treatment protocols has been deleted.SummaryDifference33%
- Check41 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check77 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check99 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check106 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page.